Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antiviral phosphinate compounds

a technology of phosphinate and compound, which is applied in the direction of peptides, drug compositions, peptides, etc., can solve the problems of limited usefulness of effects, and achieve the effects of improving oral bioavailability, enhancing activity against development, and improving inhibitory or pharmacokinetic properties

Inactive Publication Date: 2009-09-10
GILEAD SCI INC
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides a compound of formula I, which is a compound of formula I', or a prodrug or salt thereof. The compound has various structures and can be used for various purposes. The technical effect of the invention is to provide a new compound that can be used for the treatment of various diseases and disorders.

Problems solved by technology

Although drugs targeting the liver are in wide use and have shown effectiveness, toxicity and other side effects have limited their usefulness.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antiviral phosphinate compounds
  • Antiviral phosphinate compounds
  • Antiviral phosphinate compounds

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Compound 1

[0383]

[0384]Phosphonic acid intermediate (1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phosphonic acid monoethyl ester III (415 mg, 1.28 mmol) was dissolved in toluene (8 mL). This solution was cooled to 0° C. and (COCl)2 (222 μL, 2.56 mmol) was added in a drop-wise fashion. DMF (44 μL, 0.56 mmol) was then added. The reaction was run for 2 h at 0° C. and determined to be complete by 31P NMR. 31P NMR (121.4 MHz, CDCl3): δ 39.0, 38.5, 37.4, 36.5, 17.0, 16.2, 16.0, 15.4.

[0385]The reaction was concentrated to orange-yellow oil and then placed under high vacuum for 1 h. The resulting residue was dissolved in THF (6.4 mL) and this solution was cooled to −78° C. A 1.4 M solution of methyllithium in diethyl ether (1.37 mL, 1.92 mmol) was added drop-wise. After 40 min, more methyllithium (456 μL, 0.64 mmol) was added drop-wise. After 10 min, the reaction was quenched at −78° C. by the addition of sat. NH4Cl(aq.). The organic phase was diluted with EtOAc and extracte...

example 2

Preparation of Compound 2

[0389]

[0390]Phosphonic acid intermediate III (208 mg, 0.64 mmol) was dissolved in toluene (8 mL). This solution was cooled to 0° C. and (COCl)2 (111 μL, 1.28 mmol) was added in a drop-wise fashion. DMF (22 μL, 0.28 mmol) was then added. The reaction was run for 2 h at 0° C. and determined to be complete by 31P NMR. 31P NMR (121.4 MHz, CDCl3): δ 39.0, 38.5, 37.4, 36.5, 17.0, 16.2, 16.0, 15.4.

[0391]The reaction was concentrated to orange-yellow oil and then placed under high vacuum for 1 h. The resulting residue was dissolved in THF (6.4 mL) and this solution was cooled to −78° C.

[0392]A solution of EtLi in dibutyl ether (1.7 M, 566 μL, 0.96 mmol) was added drop-wise. After 40 min, more EtLi (189 μL, 0.32 mmol) was added drop-wise. After 10 min, the reaction was quenched at −78° C. by the addition of sat. NH4Cl(aq.). The organic phase was diluted with EtOAc and extracted with sat. NH4Cl(aq.) and brine. The organic phase was dried over MgSO4. Concentration of t...

example 3

Preparation of Compound 3

[0395]

[0396]Phosphonic acid intermediate III (386 mg, 1.19 mmol) was dissolved in toluene (14.9 mL). This solution was cooled to 0° C. and (COCl)2 (155 μL, 1.78 mmol) was added in a drop-wise fashion. DMF (20 μL, 0.26 mmol) was then added. The reaction was run for 2 h at 0° C. and determined to be complete by 31P NMR. 31P NMR (121.4 MHz, CDCl3): δ 39.0, 38.5, 37.4, 36.6, 17.0, 16.2, 16.1, 15.4.

[0397]The reaction was concentrated to a yellow-orange oil and then placed under high vacuum for 1 h. The resulting residue was dissolved in THF (11.9 mL) and this solution was cooled to −78° C. A 2.0 M solution of n-BuLi in pentane (595 μL, 1.19 mmol) was added drop-wise. After 40 min more n-BuLi (520 μL, 1.04 mmol) was added drop-wise. After 10 min the reaction was quenched at −78° C. by the addition of sat. NH4Cl(aq.). The organic phase was diluted with EtOAc and extracted with sat. NH4Cl(aq.) and brine. The organic phase was dried over MgSO4. Concentration of the f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Description

FIELD OF THE INVENTION[0001]The invention relates generally to phosphinate compounds with HCV inhibitory activity.BACKGROUND OF THE INVENTION[0002]Hepatitis C is recognized as a chronic viral disease of the liver which is characterized by liver disease. Although drugs targeting the liver are in wide use and have shown effectiveness, toxicity and other side effects have limited their usefulness. Inhibitors of HCV are useful to limit the establishment and progression of infection by HCV as well as in diagnostic assays for HCV.[0003]There is a need for new HCV therapeutic agents.SUMMARY OF THE INVENTION[0004]In one embodiment the invention provides a compound of the invention which is a compound of formula I:or a pharmaceutically acceptable salt, or prodrug thereof, wherein:[0005]R1 is independently selected from H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, halogen, haloalkyl, alkylsulfonamido, arylsulfonamido, —C(O)NHS(O)2—, or —S(O)2—, optionally substituted with one or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/12C07K5/083C07K5/12A61K38/06A61K38/21
CPCC07F9/65583A61P1/16A61P31/12A61P31/14A61P43/00C07D401/14A61K31/662C07D401/12
Inventor CASAREZ, ANTHONYCHAUDHARY, KLEEMCHO, AESOPCLARKE, MICHAEL O'NEIL HANRAHANDOERFFLER, EDWARDFARDIS, MARIAKIM, CHOUNG U.PYUN, HYUNG-JUNGSHENG, XIAONING C.WANG, JIANYING
Owner GILEAD SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com